As of September 12, the Democratic Republic of the Congo has recorded 7,200 confirmed Ebola cases and 3,475 deaths across seven provinces. While Ituri province remains a primary area, health authorities report encouraging signs of slower transmission in some areas even as North Kivu faces a sharp surge in new infections.
Epidemic Scale Across Seven Provinces and Current Case Fatality Rates
The current outbreak, driven by the rare Bundibugyo species of the virus, is described as the largest ever ebola outbreak and the fastest growing ebola outbreak in the Democratic Republic of the Congo. Government and international health officials tracking the spread note that transmission patterns vary widely across the affected regions.
By September 12, national totals reached 7,200 confirmed cases and 3,475 deaths. The epidemic has affected seven provinces, including Ituri, North Kivu, South Kivu, Haut-Uélé, Bas-Uélé, Tshopo, and South Ubangi.
Disparate Regional Trends: Declines in Ituri Alongside Surges in North Kivu
While national aggregates point to a continuing crisis, local trajectories tell a mixed story. Officials point to encouraging progress in parts of Ituri province and its capital, Bunia, where transmission rates have begun to slow down from previous highs. In South Kivu, authorities have registered no new cases since the end of May.
At the same time, the number of new cases and deaths per week had doubled over a two-week span in North Kivu, particularly around Butembo. North Kivu now accounts for roughly 45 percent of newly recorded weekly infections, illustrating the challenge of managing what health authorities describe as many outbreaks unfolding across a vast geographic area.
Disproportionate Impact on Women, Girls, and Frontline Caregivers
Women and girls bear a heavy share of the epidemic’s burden. Official figures cited by UN Women indicate that more than 54 percent of confirmed Ebola patients in the country are women, with girls making up 51 percent of cases in the 10 to 17 age group.
This domestic care model aligns closely with observed transmission pathways. Furthermore, the outbreak has affected women’s livelihoods, as women make up a significant number of the traders in the affected area, and is restricting access to vital maternal and reproductive health services.
Brutal Field Conditions and Logistical Hurdles for Medical Teams
Medical personnel operating in eastern regions contend with conflict-affected areas, poor road infrastructure, and community hostility. Aid organizations report that a small minority have attacked aid workers and health facilities.
Healthcare workers face elevated hazards of infection despite personal protective equipment.
Clinical Trials and the Search for Medical Countermeasures
Unlike previous outbreaks caused by the Zaire strain, for which the Ervebo vaccine is used, the Bundibugyo virus lacks a licensed vaccine specifically approved for the disease.
The Pan African Clinical Trials Registry successfully registered a Phase II clinical trial for NV-387 Oral Gummies, developed by NanoViricides as a treatment for the current Bundibugyo ebolavirus. Regulatory approval from ACOREP in the DRC cleared the path for the trial under principal investigator Patrick de Marie Chimusa Katoto.
Shipments of the oral drug arrived at trial sites in Ituri province, positioning medical teams to begin patient dosing pending final operational readiness.